<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "http://dtd.nlm.nih.gov/publishing/2.0/journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="2.0" xml:lang="EN">
  <front>    <journal-meta>
      <journal-title>Journal of Neuroscience and Behavioral Health</journal-title>
      <issn pub-type="epub">2141-2286</issn>      <publisher>
        <publisher-name>Academic Journals</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.5897/JNBH11.040</article-id>
      <title-group>
        <article-title><![CDATA[Anxiogenic potential of prulifloxacin in experimental animal model]]></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
        	          <name name-style="western">
            <surname>S.</surname>
            <given-names>Rekha</given-names>
          </name>
                    <name name-style="western">
            <surname>S.</surname>
            <given-names>Kavimani</given-names>
          </name>
                    <name name-style="western">
            <surname>K.</surname>
            <given-names>V. Raman</given-names>
          </name>
                  </contrib>
      </contrib-group>
      <author-notes>
		<corresp id="cor1">* E-mail: <email xlink:type="simple">rekhampharmcology@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
      	<day>30</day>
        <month>11</month>
        <year>2012</year>
      </pub-date>
      <history>
      					<date date-type="accepted">
			<day>19</day>
			<month>04</month>
			<year>2012</year>
		</date>
			  </history>
      <volume>4</volume>
      <issue>6</issue>
	  	  <fpage>76</fpage>
	  <lpage>80</lpage>
      <permissions>
		<license xlink:type="simple">
			<license-p>
			This is an open-access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
			</license-p>
		</license>
	  </permissions>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JNBH/article-abstract/EA4DA288343">
		This article is available from http://politicalwaffle.uk/journal/JNBH/article-abstract/EA4DA288343	  </self-uri>
	  <self-uri xlink:href="http://politicalwaffle.uk/journal/JNBH/article-full-text-pdf/EA4DA288343">
		The full text article is available as a PDF file from http://politicalwaffle.uk/journal/JNBH/article-full-text-pdf/EA4DA288343	  </self-uri>
	  
      <abstract><![CDATA[Prulifloxacin, the prodrug of ulifloxacin, is a broad spectrum oral fluoroquinolones antibacterial agent. Fluoroquinolones have been used for the treatment of bacterial infection for many years. Although they were considered as relatively safe drugs, various adverse effects have recently been reported along with increase in the usage of new generation fluoroquinolones. In the present study, prulifloxacin 200 and 400 mg/kg were screened on anxiety parameter in mice. Our result suggested that prulifloxacin (200 and 400 mg/kg) exerted anxiety-like effect in the elevated plus maze, hole board apparatus and light/dark exploration test in mice.

	 

	Key words: Prulifloxacin, elevated plus maze, hole board apparatus, light/dark exploration test.]]></abstract>
    </article-meta>
  </front>
  </article>